458 related articles for article (PubMed ID: 28855349)
1. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
2. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
[TBL] [Abstract][Full Text] [Related]
3. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Weller M; Kaulich K; Hentschel B; Felsberg J; Gramatzki D; Pietsch T; Simon M; Westphal M; Schackert G; Tonn JC; von Deimling A; Davis T; Weiss WA; Loeffler M; Reifenberger G;
Int J Cancer; 2014 May; 134(10):2437-47. PubMed ID: 24614983
[TBL] [Abstract][Full Text] [Related]
4. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
6. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
Lee M; Kang SY; Suh YL
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
[TBL] [Abstract][Full Text] [Related]
7. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
[TBL] [Abstract][Full Text] [Related]
10. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
11. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
[TBL] [Abstract][Full Text] [Related]
14. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
[TBL] [Abstract][Full Text] [Related]
15. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
16. Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas.
Carvalho PO; Uno M; Oba-Shinjo SM; Rosemberg S; Wakamatsu A; da Silva CC; Teixeira MJ; Marie SK
Int J Biol Markers; 2014 Jun; 29(2):e120-8. PubMed ID: 24170555
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
Chen JR; Xu HZ; Yao Y; Qin ZY
Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Hobbs J; Nikiforova MN; Fardo DW; Bortoluzzi S; Cieply K; Hamilton RL; Horbinski C
Am J Surg Pathol; 2012 Aug; 36(8):1186-93. PubMed ID: 22472960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]